Joan Albanell-Pallares - Publications

LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer.

Journal: Nature cancer

Published: February 04, 2021

Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 30, 2020

High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer.

Journal: Cancer immunology research

Published: December 13, 2018

NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 24, 2018

Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: June 20, 2018

Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer.

Journal: Nature cell biology

Published: April 21, 2018

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy.

Journal: Oncotarget

Published: March 07, 2018

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.

Journal: JAMA oncology

Published: February 10, 2018

p95HER2-T cell bispecific antibody for breast cancer treatment.

Journal: Science translational medicine

Published: January 29, 2018

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

Journal: Investigational new drugs

Published: December 21, 2017

Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma.

Journal: Clinical lung cancer

Published: December 04, 2017

Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Journal: Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia

Published: November 28, 2017